Currently Enrolling Clinical Trials - Updated March 15, 2011
























Amyloid Plaque

Sagittal Section of Brain

Type of Drug Phase Stage Add-On Placebo Duration Open Label
Anti-hypotensive III Any Standard Therapy Yes 12 weeks Yes
Antipsychotic III Any Standard Therapy Yes 12 weeks Yes

Electroencephalogram

Type of Seizures Type of Drug Phase Add-On VNS Allowed Placebo Duration Open Label
Partial Seizures Slow sodium-channel modulator III No No No 30 weeks Yes
Partial Seizures Fast sodium-channel blocker III Yes Yes 33% 22 weeks 1 year
Partial Seizures Fast sodium-channel blocker III No Yes No 18 weeks 1 year
Partial Seizures Once daily fast sodium-channel blocker III Yes Yes 33% 35 weeks Yes
Partial Seizures AMPA receptor blocker III Yes Yes 33% 25 weeks Yes

MRI in MS

Subtype of MS Type of Drug Phase Add-On Placebo Duration Open Label
Relapsing-Remitting Oral Immunomodulator III No 25% get standard therapy 6 months Yes
Relapsing-Remitting Interferon plus Oral Immunomodulator III Yes 33% 24 months Yes
First Clinical Episode Suggestive of MS Oral Immunomodulator III Yes 33% 24-30 months Yes
Injectable 3x/wk Protein Immunomodulator III Yes 50% 6 months No

Foot with nerves

Type of Drug Phase Add-On Placebo Duration Open Label
α2δ-modulator III No 50% 4 months None


Contact Us

If you or a loved one is interested in participating in one of our trials, please contact us at (866) 829-1919 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

- Stephen S. Flitman, MD, Principal Investigator

Your Name
Name of Patient
Your Telephone
Best Time to Call
Trial Type
Comments
 Ready?
If you are already a patient in the practice and need to reach the doctor on call, do not use this form; call 602-265-6500 directly

   

| HOME | ORGANIZATION | FOCUS| EDUCATION| RESEARCH | CONTACT US|

Visitors since 01/01/01

Copyright © 2001-2011
21st Century Neurology, a division of Xenoscience